Shares in Texan pharma company Reata Pharmaceuticals (Nasdaq: RETA) closed 15% lower on Wednesday.
The company had earlier revealed a setback with Skyclarys (omavaloxolone), which in March became the first drug to win US Food and Drug Administration (FDA) approval to specifically treat the rare neuromuscular disease Friedreich's ataxia.
In presenting its first-quarter financial results, Reata gave an update on its progress with bringing the Nrf2 activator to market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze